These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 29468947)
1. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary. Cree BA Mult Scler; 2018 Aug; 24(9):1161-1162. PubMed ID: 29468947 [No Abstract] [Full Text] [Related]
2. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No. Wallin MT Mult Scler; 2018 Aug; 24(9):1159-1161. PubMed ID: 29468931 [No Abstract] [Full Text] [Related]
3. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes. Piehl F; Hillert J Mult Scler; 2018 Aug; 24(9):1157-1159. PubMed ID: 29468952 [No Abstract] [Full Text] [Related]
13. [Primary progressive multiple sclerosis: a treatment turns out to be finally effective]. Lalive PH Rev Med Suisse; 2016 Mar; 12(508):472-3. PubMed ID: 27089606 [No Abstract] [Full Text] [Related]
14. New biological agents in the treatment of multiple sclerosis. Buc M Bratisl Lek Listy; 2018; 119(4):191-197. PubMed ID: 29663814 [TBL] [Abstract][Full Text] [Related]
15. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis]. Midaglia L; Mora L; Mulero P; Sastre-Garriga J; Montalban X Rev Neurol; 2018 Jan; 66(1):25-32. PubMed ID: 29251340 [TBL] [Abstract][Full Text] [Related]
16. Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient. Marrodan M; Laviano J; Oneto S; Reino FM; Delorme R; Fornillo F; Férnandez J; Correale J Neurol Sci; 2021 Sep; 42(9):3893-3895. PubMed ID: 34075515 [No Abstract] [Full Text] [Related]
17. New Inroads Against Multiple Sclerosis. Lyon J JAMA; 2018 Jan; 319(1):9-11. PubMed ID: 29238808 [No Abstract] [Full Text] [Related]
18. Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy. Sormani MP; De Stefano N Neurology; 2014 Apr; 82(17):1484-5. PubMed ID: 24682968 [No Abstract] [Full Text] [Related]
19. Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis. Capasso N; Nozzolillo A; Scalia G; Lanzillo R; Carotenuto A; De Angelis M; Petruzzo M; Saccà F; Russo CV; Brescia Morra V; Moccia M Mult Scler Relat Disord; 2021 Apr; 49():102802. PubMed ID: 33556652 [TBL] [Abstract][Full Text] [Related]